Descriptive Statistics for 30 days outcome in clinical subgroups
| Total | Non-HPR | Individualised | |
|---|---|---|---|
| STEMI cohort | 93 | 31 (33%) | 62 (67%) |
| Cardiovascular death | 8 (8.6%) | 4 (12.9%) | 4 (6.5%) |
| Non-shock | 1 (1.1%) | 1 (3.2%) | 0 (0%) |
| Cardiogenic shock (n=shock patients; % of shock) | 7 (17; 41%) | 3 (6; 50%) | 4 (11; 36%) |
| Myocardial infarction Stent thrombosis | 0 (0%) | 0 (0%) | 0 (0%) |
| Definite | 0 (0%) | 0 (0%) | 0 (0%) |
| Probable | 0 (0%) | 0 (0%) | 0 (0%) |
| Bleeding | |||
| TIMI major and minor | 6 (6.5%) | 3 (9.7%) | 3 (4.8%) |
| TIMI major | 4 (4.3%) | 2 (6.5%) | 2 (3.2%) |
| TIMI minor | 2 (2.2%) | 1 (3.2%) | 1 (1.6%) |
| Type | |||
| Instrumented | 5 (5.4%) | 3 (9.7%) | 2 (3.2%) |
| Spontaneous | 1 (1.1%) | 0 (0%) | 1 (1.6%) |
| NSTE-ACS cohort | 446 | 303 (68%) | 143 (32%) |
| Cardiovascular death | 10 (2.2%) | 5 (1.7%) | 5 (3.5%) |
| Non-shock | 7 (1.6%) | 3 (1.0%) | 4 (2.8%) |
| Cardiogenic shock (n=shock patients; % of shock) | 3 (9; 33%) | 2 (2; 100%) | 1 (7; 14%) |
| Myocardial infarction Stent thrombosis | 1 (0.2%) | 1 (0.3%) | 0 (0%) |
| Definite | 1 (0.2%) | 1 (0.3%) | 0 (0%) |
| Probable | 2 (0.4%) | 2 (0.7%) | 0 (0%) |
| Bleeding | |||
| TIMI major and minor | 13 (2.9%) | 9 (3.0%) | 4 (2.8%) |
| TIMI major | 4 (0.9%) | 2 (0.7%) | 2 (1.4%) |
| TIMI minor | 9 (2.0%) | 7 (2.3%) | 2 (1.4%) |
| Type | |||
| Instrumented | 5 (1.1%) | 4 (1.3%) | 1 (0.7%) |
| Spontaneous | 8 (1.8%) | 5 (1.7%) | 3 (2.1%) |
| Stable CAD cohort | 468 | 330 (70%) | 138 (30%) |
| Cardiovascular death | 0 (0%) | 0 (0%) | 0 (0%) |
| Myocardial infarction Stent thrombosis | 0 (0%) | 0 (0%) | 0 (0%) |
| Definite | 0 (0%) | 0 (0%) | 0 (0%) |
| Probable | 0 (0%) | 0 (0%) | 0 (0%) |
| Bleeding | |||
| TIMI major and minor | 7 (1.5%) | 5 (1.5%) | 2 (1.4%) |
| TIMI major | 2 (0.4%) | 2 (0.6%) | 0 (0%) |
| TIMI minor | 5 (1.1%) | 3 (0.9%) | 2 (1.4%) |
| Type | |||
| Instrumented | 4 (0.8%) | 3 (0.9%) | 1 (0.7%) |
| Spontaneous | 3 (0.6%) | 2 (0.6%) | 1 (0.7%) |
CAD, coronary artery disease; HPR, high on-treatment platelet reactivity; NSTE-ACS, non-ST-elevation acute coronary syndrome; ns, not significant; STEMI, ST-elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.